In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on November 2025.

According to the body, patient participation in industry-sponsored trials has fallen by 25% between 2022/23 and 2024/25.

Crucially, 41% of these candidates target pathogens for which no vaccines or prophylactic monoclonal antibodies are currently registered.

A wearable device that can alert patients and caregivers minutes before a seizure occurs is set to launch across Europe.

The two companies have launched a collaborative research initiative to investigate anhedonia in depression, hoping to solve huge unmet needs.

Scotland has announced a major new plan to grow its life sciences sector, aiming to boost economic growth and healthcare innovation.

Novartis is the latest pharma company to announce a new plant in the US, selecting North Carolina’s ‘Research Triangle’ district as its home.

AbbVie has released ‘Second Winds’, which captures the lived experience of three people diagnosed with chronic lymphocytic leukaemia.